China SXT Pharmaceuticals, Inc.(SXTC)Earnings, Financials & Key Ratios
SXTC•NASDAQ
$2.50
Price updated Jul 6, 2026
SectorHealthcareIndustrySpecialty & Generic PharmaSub-IndustryTraditional Chinese medicine producers
AboutChina SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine piece tablets (TCMP) in China. The company offers advanced, fine, and regular TCMP products, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. As of March 31, 2022, it had an end-customer base of 68 pharmaceutical companies, 14 chain pharmacies, and 20 hospitals in 10 provinces and municipalities in China. The company was founded in 2005 and is headquartered in Taizhou, China.Show more
- Revenue$2M-9.7%
- EBITDA-$3M-12.4%
- Net Income-$3M-6.6%
- EPS (Diluted)-8.18-129.1%
- Gross Margin21.11%-26.5%
- EBITDA Margin-149.24%-24.5%
- Operating Margin-153.97%-18.1%
- Net Margin-189.77%-18.1%
- ROE-22.5%-3.9%
SXTC Price & Volume
China SXT Pharmaceuticals, Inc. (SXTC) stock price & volume — 10-year historical chart
Loading chart...
Persistent Revenue Contraction Challenges Operational Sustainability
Investment Thesis • Updated 2025Q4
VerdictNeutral
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Unsustainable Operational Cash Burn
Key Thesis Takeaways
- China SXT Pharmaceuticals faces a precarious outlook characterized by a persistent revenue decline, with quarterly figures recently stagnating at $455.7K.
- The company's inability to scale operations is evidenced by SG&A expenses of $1.1M consistently outpacing gross profits, leading to significant value destruction reflected in a $28.0 million retained earnings deficit.
- Investors should remain cautious as the firm's reliance on a $18.1 million cash buffer masks an underlying business model that currently lacks a path to operational self-sufficiency.
Verdict Logic
Negative: The company's fundamental viability is undermined by an operating margin of -153.97% and a persistent reliance on cash reserves to offset ongoing net losses of $1.3 million per quarter.
SXTC Growth Metrics
China SXT Pharmaceuticals, Inc. (SXTC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-19.54%
3 Years-12.54%
TTM-27.41%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM58.43%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM76.69%
Return on Capital
10 Years16.12%
5 Years-24.02%
3 Years-23.58%
Last Year-17.94%
Peers Comparison
Key metrics vs top competitors for China SXT Pharmaceuticals, Inc. (SXTC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.50 | $1.01M | -0.31 | -9.73% | -189.77% | -22.5% | — | |
| $2.18 | $1.09M | -0.15 | 4.11% | -17.01% | -25.58% | — | |
| $3.84 | $4.82M | -26.61 | — | — | -1.45% | — | |
| $30.65 | $691.35M | 37.38 | 12.47% | 5.91% | 9.7% | — | |
| $9.67 | $109.08M | 26.14 | 30.75% | 17.66% | 8.33% | — | |
| $13.20 | $426.79M | -4.51 | -21.56% | -9.84% | -27.1% | — |
Compare SXTC vs Peers
China SXT Pharmaceuticals, Inc. (SXTC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when SXTC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SXTC Frequently Asked Questions
China SXT Pharmaceuticals, Inc. (SXTC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is China SXT Pharmaceuticals, Inc.'s revenue?
China SXT Pharmaceuticals, Inc. (SXTC) reported $1.7M in revenue for fiscal year 2025. This represents a 53% decrease from $3.7M in 2016.
How fast is China SXT Pharmaceuticals, Inc. growing?
China SXT Pharmaceuticals, Inc. (SXTC) saw revenue decline by 9.7% over the past year.
Is SXTC profitable?
China SXT Pharmaceuticals, Inc. (SXTC) reported a net loss of $3.3M for fiscal year 2025.
Dividend & Returns
What is SXTC's return on equity?
China SXT Pharmaceuticals, Inc. (SXTC) has a return on equity (ROE) of -22.5%. Negative ROE indicates the company is unprofitable.
What is China SXT Pharmaceuticals, Inc.'s free cash flow?
China SXT Pharmaceuticals, Inc. (SXTC) had negative free cash flow of $2.3M in fiscal year 2025, likely due to heavy capital investments.